AbbVie's 2Q Revenue up 34%

AbbVie

2Q Revenues: $13.9 billion (+34%)

2Q Earnings: $769 million (loss of $739 million 2Q20)

Comments: Global revenues from the Immunology portfolio were $6.1 billion, up 15% with U.S. Humira sales of $4.3 billion, an increase of 7% while International Humira sales were $811 million, down 6% due to biosimilar competition; Global Skyrizi sales reached $674 million, +>100% and Global Rinvoq revenues were $378 million, +>100%. Global revenues from the Hematologic Oncology portfolio were $1.8 billion, up 14%; Global Imbruvica sales were $1.4 billion, up 7%, with U.S. sales of $1.1 billion and International Profit Sharing of $282 million; Global Venclexta sales were $435 million, up 38%.Global revenues from the Neuroscience portfolio were $1.5 billion; Global Botox Therapeutic sales were $603 million, up 39%; Global Vraylar sales were $432 million, up 26%. Global sales from the Aesthetics portfolio were $1.4 billion; Global Botox Cosmetic sales were $584 million, +>100%.